 WARREN, N.J., May 11, 2021 GLOBE NEWSWIRE -- Bellerophon Therapeutics, Inc. Nasdaq: BLPH Bellerophon or the Company, a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the first quarter ended March 31, 2021. 